An observational, prospective, two-cohort comparison of a fixed *versus* variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies

Nakisa Khorsand,[1] Nic J.G.M. Veeger,[2] Reinier M. van Hest,[1,3] Paula F. Ypma,[4] Jeroen Heidt,[5] and Karina Meijer[6]

[1]Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague; [2]Department of Epidemiology, University Medical Centre, Groningen; [3]Department of Clinical Pharmacy, Academic Medical Center, Amsterdam; [4]Department of Haematology, Haga Teaching Hospital, The Hague; [5]Department of Internal Medicine, Medical Centre Haaglanden, The Hague; and [6]Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, The Netherlands

Citation: Khorsand N, Veeger NJGM, van Hest RM, Ypma PF, Heidt J, and Meijer K. An observational, prospective, two-cohort comparison of a fixed versus *variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 2012;97(10):1501-1506. doi:10.3324/haematol.2012.063701*

Online Supplementary Table S1. PCC variable dosing regimen

Initial INR →		7.5	5.9	4.8	4.2	3.6	3.3	3.0	2.8	2.6	2.5	2.3	2.2
	↓ Body weight (kg)												
Target	50	1040	1040	1040	780	780	780	520	520	X	X	X	X
INR	60	1300	1300	1040	1040	780	780	780	520	X	X	X	X
≤2.1	70	1560	1300	1300	1300	1040	1040	780	780	X	X	X	X
	80	1560	1560	1560	1300	1300	1040	1040	780	X	X	X	X
	90	1560	1560	1560	1560	1300	1300	1040	780	X	X	X	X
	100	1560	1560	1560	1560	1560	1300	1040	1040	X	X	X	X
Target	50	1560	1560	1560	1300	1300	1300	1040	1040	780	780	780	780
INR	60	2080	1820	1820	1560	1560	1560	1300	1300	1040	1040	1040	780
≤1.5	70	2340	2080	2080	1820	1820	1820	1560	1560	1300	1040	1040	1040
	80	2600	2600	2340	2340	2340	2080	2080	1820	1560	1300	1300	1040
	90	2600	2600	2600	2340	2340	2340	2080	2080	1820	1560	1300	1040
	100	2600	2600	2600	2600	2600	2340	2340	2080	1820	1820	1560	1300

The dosage is shown as International Units of Factor IX, based on a Cofact® batch with 26 IU of F IX per mL as used for this study. This table is based on the manufacturer's algorithm (Sanquin, Amsterdam, The Netherlands).